Search
Desogestrel
go.drugbank.com/drugs/DB00304ApprovedInvestigationalDesogestrel, a prodrug, is a third generation progestogen[A176315] and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. … [F4127] In the US, desogestrel is found only in combination with [ethinyl estradiol].
Mixtures: DESOGESTREL E ETINILESTRADIOLO ARISTO, DESOGESTREL E ETINILESTRADIOLO ARISTOCategories: Sex Hormones and Modulators of the Genital SystemInsulin detemir
go.drugbank.com/drugs/DB01307ApprovedInvestigationalin the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. … has been caused to pancreatic cells that the body is no longer able to produce insulin on its own.
Cisatracurium
go.drugbank.com/drugs/DB00565ApprovedInvestigational[A243416] Compared to atracurium, cisatracurium produces a lower degree of histamine release.[A253597] … Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate.
Smallpox (Vaccinia) Vaccine, Live
go.drugbank.com/drugs/DB14711ApprovedInvestigationalThe New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. … [L12747] In August 2024, ACAM2000 was additionally approved for the prevention of mpox infection in high-risk individuals.[L51499]
Moroctocog alfa
go.drugbank.com/drugs/DB13999Approvedfibrinogen to fibrin, the fibrous protein that creates the scaffold of the clot. … Also known as Anti-Hemophilic Factor (AHF), endogenous Factor VIII is essential to the clotting process in the body due to its involvement in the clotting cascade where it is responsible for acting as
Products: REFACTO AF 500 IU IV ENJEKSIYONLUK COZELTI ICIN TOZ VE COZUC FLAKON, 1 ADET, REFACTO AF 250 IU IV ENJEKSIYONLUK COZELTI ICIN TOZ VE COZUCU FLAKON, 1 ADETDeucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigationalUnlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity … [A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.
Methoxyflurane
go.drugbank.com/drugs/DB01028ApprovedInvestigationalVet approvedWithdrawnIf so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular … (From AMA Drug Evaluations Annual, 1994, p180) In the US, methoxyflurane is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness.[L43942]
Acetohydroxamic acid
go.drugbank.com/drugs/DB00551ApprovedInvestigationalAcetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. … It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.
Enfuvirtide
go.drugbank.com/drugs/DB00109ApprovedInvestigationalEnfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake … The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.
Imatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigationalThe discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. … [L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]